## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Proposed Single Technology Appraisal**

# Nintedanib for treating idiopathic pulmonary fibrosis [ID752]

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
<ul> <li>Boehringer Ingelheim (nintedanib)</li> <li>Patient/carer groups</li> <li>Action For Pulmonary Fibrosis</li> <li>Afiya Trust</li> <li>Black Health Agency</li> <li>British Lung Foundation</li> <li>Equalities National Council</li> <li>Muslim Council of Britain</li> <li>Muslim Health Network</li> <li>Pulmonary Fibrosis Trust</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Professional groups</li> <li>Association for Respiratory Technology and Physiology</li> <li>Association of Respiratory Nurse Specialists</li> <li>British Geriatrics Society</li> <li>British Thoracic Society</li> <li>Primary Care Respiratory Society</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Physicians</li> <li>Royal Society of Medicine – Intellectual Disabilities Forum</li> </ul>	<ul> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Alliance</li> <li>NHS Commercial Medicines Unit</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Possible comparator manufacturer(s)</li> <li>InterMune (pirfenidone)</li> <li>Martindale Pharmaceuticals (Nacetylcysteine)</li> <li>Teva UK (Nacetylcysteine)</li> <li>Relevant research groups</li> <li>Breathing Matters</li> <li>British Association for Lung Research</li> <li>Cochrane Airways Group</li> <li>Health Research Authority</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> </ul>
<ul> <li>UK Clinical Pharmacy Association</li> <li>Others</li> <li>Department of Health</li> <li>NHS England</li> <li>NHS Nottingham City CCG</li> <li>NHS Merton CCG</li> </ul>	<ul> <li>Evidence Review Group</li> <li>Evidence Review Group tbc</li> <li>National Institute for Health Research Health Technology Assessment Programme</li> </ul>

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of nintedanib for treating idiopathic

pulmonary fibrosis

Issue date: June 2014 Page 1 of 3

# Appendix C

Consultees	Commentators (no right to submit or appeal)
Welsh Government	Associated Guideline groups  National Clinical Guidelines Centre  Associated Public Health groups  Public Health England  Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Issue date: June 2014 Page 2 of 3

#### **Definitions:**

## Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

## Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the British National Formulary.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

National Institute for Health and Care Excellence Provisional matrix for the proposed technology appraisal of nintedanib for treating idiopathic pulmonary fibrosis Page 3 of 3

Issue date: June 2014

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.